The anticipation of price changes announced by the government at the beginning of the year and implemented consecutively in June and September, led to a decrease in inventory levels throughout the supply chain and consequently to a significant drop in sales, influencing the gross margins...
Consolidated Turnover was formulated at Euro 122,8 million opposed to Euro 119,7 million during the H1 of 2008. The significant retention of operating expenses (-14,0%) improved operating results of the Group, which concluded to profits of Euro 2,6 million opposed to losses of Euro 1,3...
Lavipharm SA, according to the obligations deriving from 3/347/12.07.2005 of the Capital Market Committee, announces that Mrs. Ioanna Tsireka assumes the responsibility of Human Resources Director at Lavipharm Group replacing Mrs. Helen Markou. Mrs. Markou will continue to contribute to Lavipharm as Management Advisor in...
Profitability and constant growth highlight Lavipharm Group financial results of 9M 2009, maintaining its positive course since the beginning of the year. Consolidated Turnover reached Euro 182,9 million compared to Euro 176,4 million during the 9M of 2008. The significant decrease in operating expenses (-14,9%)...
